Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
A graphic memoir documents clinical and ethical disagreements and decision points throughout a paramedic team’s time with an incarcerated patient in labor.
AMA J Ethics. 2019;21(10):E902-903. doi:
10.1001/amajethics.2019.902.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?
Going to so-called safety-net clinics could mean being subject to different standards of care than those in other health care delivery settings. Learners who understand social determinants of health might be able to help patients navigate the system and access community resources.
AMA J Ethics. 2019;21(1):E44-49. doi:
10.1001/amajethics.2019.44.
In this special edition of Ethics Talk, Dr Uché Blackstock joins us to discuss COVID-19 morbidity and mortality outcomes inequity by race and what needs to change now and postpandemic. Transcript available.